Inflammasome Therapeutics reported Phase 2 results showing its K8 slowed GA lesion growth by 54% and delivered a 4.0-letter vision advantage at six months. The company is planning Phase 3 following these data.
Inflammasome Therapeutics reported Phase 2 results showing its K8 slowed GA lesion growth by 54% and delivered a 4.0-letter vision advantage at six months. The company is planning Phase 3 following these data.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
